Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 4, July-August, p. 579–584

Publication type: review article

Language: English

The Influence of Genetic RFC1, MS and MTRR Polymorphisms on the Risk of Acute Lymphoblastic Leukemia Relapse in Children and the Adverse Effects of Methotrexate

Wpływ polimorfizmów genetycznych RFC1, MS, MTRR na ryzyko nawrotu ostrej białaczki limfoblastycznej u dzieci i nasilenie działań niepożądanych po zastosowaniu metotreksatu

Ewa Niedzielska1,A,B,C,D, Jadwiga Węcławek-Tompol1,B,C,E, Agnieszka Matkowska-Kocjan2,C,E, Alicja Chybicka1,E,F

1 Department and Clinic of Pediatric Oncology, Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland

2 Department and Clinic of Pediatric Infectious Diseases, Wroclaw Medical University, Wrocław, Poland

Streszczenie

Polimorfizm z zakresu genów kodujących enzymy metabolizujące leki może stanowić podłoże indywidualnych różnic skuteczności i toksyczności wielu preparatów, w tym cytostatyków. Chociaż w ostatnich latach zastosowanie intensywnych metod leczenia wpłynęło na poprawę rokowania w białaczkach, nadal obserwuje się dużą liczbę działań niepożądanych podczas samej terapii, związaną z nieswoistością działania i wąskim współczynnikiem terapeutycznym leków przeciwnowotworowych. Oznaczenie wybranych polimorfizmów genetycznych może pomóc zindywidualizować terapię i wpłynąć na poprawę bezpieczeństwa oraz skuteczność leczenia.

Key words

polymorphism, methotrexate, acute lymphoblastic leukemia, adverse effects.

Słowa kluczowe

polimorfizm, metotreksat, ostra białaczka limfoblastyczna, działania niepożądane.

References (31)

  1. Sierra EE, Goldman ID: Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol. 1999 Apr, 26 (2 Suppl 6), 11–23.
  2. Figueiredo JC, Levine AJ, Lee WH, Conti DV, Poynter JN, Campbell PT, Duggan D, Lewinger JP, Martinez ME, Ulrich CM, Newcomb P, Potter J, Limburg PJ, Hopper J, Jenkins MA, Le Marchand L, Baron JA, Haile RW: Genes involved with folate uptake and distribution and their association with colorectal cancer risk. Cancer Causes Control. 2010 Apr, 21(4), 597–608. Epub 2009 Dec 27.
  3. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailview&TermToSearch=6573
  4. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA: Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996 Dec, 5(12), 1867–1874.
  5. http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/216359
  6. http://www.drugs.com/sfx/methotrexate-side-effects.html
  7. http://indeks.mp.pl/desc.php?id=544
  8. Chango A, Emery-Fillon N, de Courcy GP, et al.: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000, 70, 310–315.
  9. Whetstine JR, Gifford AJ, Witt T, et al.: Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001, 7, 3416–3422.
  10. Laverdičre C, Chiasson S, Costea I, Moghrabi A, Krajinovic M: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002 Nov 15, 100(10), 3832–3834.
  11. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K: Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007 52 (2), 166–171. Epub 2006 Dec 19.
  12. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, Torii C, Yoshihara H, Tanigawara Y, Takahashi T, Kosaki K: Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006 Feb, 28(2), 64–68.
  13. Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, Thomas R, Taub JW, Matherly LH: Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Clin Cancer Res 2007 Jan 15, 13 (2 Pt 1), 451–457.
  14. Yates Z, Lucock M: G80A reduced folate carrier SNP modulates cellular uptake of folate and affords protection against thrombosis via a non homocysteine related mechanism. Life Sci 2005, 77, 2735–2742.
  15. Momparler RL, Bovenzi V: DNA methylation and cancer. Cell Physiol 2000 May, 183(2), 145–154.
  16. Lightfoot TJ, Skibola CF, Willett EV, et al.: Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomarkers Prev 2005, 14, 2999–3003.
  17. Skibola CF, Forrest MS, Coppede F, et al.: Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004, 104, 2155–2162.
  18. Relton CL, Wilding CS, Laffling AJ, et al.: Low erythrocyte folate status and polymorphic variation in folaterelated genes are associated with risk of neural tube defect pregnancy. Mol Genet Metab 2004, 81, 273–281.
  19. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML: Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005, 14, 2509–2516.
  20. de Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ, Peters GJ, Ravindranath Y, Pieters R, Lindemans J: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005 Jul 15, 106(2), 717–720. Epub 2005 Mar 29.
  21. de Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, Peters GJ, Pieters R.: Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009 Mar 5, 113(10), 2284–2289. Epub 2008 Nov 19.
  22. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C: The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010 Jun 10, 115(23), 4671–4677. Epub 2010 Mar 24.
  23. Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, Raimondi S, Pui CH, Relling MV, Evans WE: Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999 Mar 1, 93(5), 1643–1650.
  24. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH: Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res 1998 Sep, 4(9), 2169–2177.
  25. Pietrzyk JJ, Bik-Multanowski M, Balwierz W, Skoczen S, Wojcik D, Chybicka A, Sikorska-Fic B, Matysiak M, Szczepanski T, Sonta-Jakimczyk D, Ploszynska A, Balcerska A, Mycko K, Bodalski J, Krawczuk-Rybak M, Kowalczyk J, Koltan A, Sobol G, Derwich K, Kwinta P: Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene. Pediatr Blood Cancer 2009 Mar, 52(3), 364–368.
  26. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M: Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006 Aug, 91(8), 1113–1116. Epub 2006 Jul 25.
  27. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R: Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008 Sep, 22(9), 1798–1800. Epub 2008 Mar 27.
  28. Gemmati D, Ongaro A, Scapoli GL, Della Porta M, Tognazzo S, Serino ML, Di Bona E, Rodeghiero F, Gilli G, Reverberi R, Caruso A, Pasello M, Pellati A, De Mattei M: Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma in adults. Cancer Epidemiol Biomarkers Prev 2004 May, 13(5), 787–794.
  29. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999 Oct 26, 96 (22), 12810–12815.
  30. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, Kondoh E, Maeda S, Asakura S, Kaba S, Nakamura S, Seto M, Morishima Y, Tajima K: Association between polymorphisms of folateand methioninemetabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001 May 15, 97(10), 3205–3209.
  31. Świerkot J, Ślęzak R, Karpiński P, Pawłowska J, Noga L, Szechiński J, Wiland P: Effect of methylenetetrahydrofolate reductase polymorphism on toxicity and efficacy of methotrexate in patients with rheumatoid arthritis. Reumatologia 2010, 48, 2, 81–93.
© Wroclaw Medical University